Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65


Relationship between sleep and exercise as colorectal cancer survivors transition off treatment.

Coles T, Bennett AV, Tan X, Battaglini CL, Sanoff HK, Basch E, Jensen RE, Reeve BB.

Support Care Cancer. 2018 Feb 22. doi: 10.1007/s00520-018-4110-8. [Epub ahead of print]


The incremental value of a geriatric assessment-derived three-item scale on estimating overall survival in older adults with cancer.

Nishijima TF, Deal AM, Lund JL, Nyrop KA, Muss HB, Sanoff HK.

J Geriatr Oncol. 2018 Feb 7. pii: S1879-4068(18)30022-5. doi: 10.1016/j.jgo.2018.01.007. [Epub ahead of print]


Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors.

Nishijima TF, Deal AM, Williams GR, Sanoff HK, Nyrop KA, Muss HB.

Oncologist. 2018 Jan 25. pii: theoncologist.2017-0559. doi: 10.1634/theoncologist.2017-0559. [Epub ahead of print]


Sleep quality in individuals diagnosed with colorectal cancer: Factors associated with sleep disturbance as patients transition off treatment.

Coles T, Tan X, Bennett AV, Sanoff HK, Basch E, Jensen RE, Reeve BB.

Psychooncology. 2018 Mar;27(3):1050-1056. doi: 10.1002/pon.4595. Epub 2017 Dec 19.


Patient-Reported Comorbidity and Survival in Older Adults with Cancer.

Williams GR, Deal AM, Lund JL, Chang Y, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K, Sanoff HK.

Oncologist. 2017 Dec 14. pii: theoncologist.2017-0404. doi: 10.1634/theoncologist.2017-0404. [Epub ahead of print]


Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.

Ray EM, Sanoff HK.

J Hepatocell Carcinoma. 2017 Nov 8;4:131-138. doi: 10.2147/JHC.S124366. eCollection 2017. Review.


The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.

Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):413-417. doi: 10.1007/s00280-017-3487-2. Epub 2017 Nov 20.


RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013.

Murphy CC, Sanoff HK, Stitzenberg KB, Baron JA, Sandler RS, Yang YC, Lund JL.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx104. No abstract available.


Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States.

Lund JL, Sanoff HK, Peacock Hinton S, Muss HB, Pate V, Stürmer T.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):41-49. doi: 10.1158/1055-9965.EPI-17-0523. Epub 2017 Oct 4.


Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.

Cole AL, Sanoff HK, Dusetzina SB.

JAMA Intern Med. 2017 Nov 1;177(11):1679-1680. doi: 10.1001/jamainternmed.2017.2788. No abstract available.


Frailty and skeletal muscle in older adults with cancer.

Williams GR, Deal AM, Muss HB, Weinberg MS, Sanoff HK, Guerard EJ, Nyrop KA, Pergolotti M, Shachar SS.

J Geriatr Oncol. 2018 Jan;9(1):68-73. doi: 10.1016/j.jgo.2017.08.002. Epub 2017 Aug 24.


Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the Association With Mortality Among Older Adults With Cancer.

Guerard EJ, Deal AM, Chang Y, Williams GR, Nyrop KA, Pergolotti M, Muss HB, Sanoff HK, Lund JL.

J Natl Compr Canc Netw. 2017 Jul;15(7):894-902. doi: 10.6004/jnccn.2017.0122.


Immortal time bias or sorafenib effect in elderly patients with HCC?

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB.

Hepatology. 2017 Aug;66(2):678-679. doi: 10.1002/hep.29250. Epub 2017 Jun 28. No abstract available.


Reply to C.D. Woodrell et al.

Sanoff HK, Chang Y, Reimers M, Lund J.

J Oncol Pract. 2017 Jun;13(6):406. doi: 10.1200/JOP.2017.022962. Epub 2017 May 15. No abstract available.


Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia?

Williams GR, Deal AM, Muss HB, Weinberg MS, Sanoff HK, Nyrop KA, Pergolotti M, Shachar SS.

Oncotarget. 2017 May 16;8(20):33658-33665. doi: 10.18632/oncotarget.16866.


Data Linkage to Improve Geriatric Oncology Research: A Feasibility Study.

Lund JL, Meyer AM, Deal AM, Choi BJ, Chang Y, Williams GR, Pergolotti M, Guerard EJ, Muss HB, Sanoff HK.

Oncologist. 2017 Aug;22(8):1002-1005. doi: 10.1634/theoncologist.2016-0418. Epub 2017 Apr 13.


Targeting HER2 beyond progression in gastroesophageal cancer.

Sanoff HK.

Lancet Oncol. 2017 May;18(5):562-564. doi: 10.1016/S1470-2045(17)30102-X. Epub 2017 Mar 23. No abstract available.


Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease.

Murphy CC, Sanoff HK, Stitzenberg KB, Baron JA, Lund JL, Sandler RS.

J Cancer Epidemiol. 2017;2017:4024580. doi: 10.1155/2017/4024580. Epub 2017 Jan 23.


Psychometric evaluation and design of patient-centered communication measures for cancer care settings.

Reeve BB, Thissen DM, Bann CM, Mack N, Treiman K, Sanoff HK, Roach N, Magnus BE, He J, Wagner LK, Moultrie R, Jackson KD, Mann C, McCormack LA.

Patient Educ Couns. 2017 Jul;100(7):1322-1328. doi: 10.1016/j.pec.2017.02.011. Epub 2017 Feb 10.


Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma.

Sanoff HK, Chang Y, Reimers M, Lund JL.

J Oncol Pract. 2017 Mar;13(3):e197-e206. doi: 10.1200/JOP.2016.017814. Epub 2016 Dec 28.


Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population-based Screening.

Murphy CC, Sandler RS, Sanoff HK, Yang YC, Lund JL, Baron JA.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):903-909.e6. doi: 10.1016/j.cgh.2016.08.037. Epub 2016 Sep 5.


Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB.

Oncologist. 2016 Sep;21(9):1113-20. doi: 10.1634/theoncologist.2015-0478. Epub 2016 May 16.


Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.

Lund JL, Sturmer T, Sanoff HK.

J Geriatr Oncol. 2016 May;7(3):176-86. doi: 10.1016/j.jgo.2016.01.011. Epub 2016 Feb 23.


A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.

McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH.

Invest New Drugs. 2015 Dec;33(6):1225-31. doi: 10.1007/s10637-015-0298-3. Epub 2015 Oct 21.


Prevalence of sarcopenia in older patients with colorectal cancer.

Broughman JR, Williams GR, Deal AM, Yu H, Nyrop KA, Alston SM, Gordon BB, Sanoff HK, Muss HB.

J Geriatr Oncol. 2015 Nov;6(6):442-5. doi: 10.1016/j.jgo.2015.08.005. Epub 2015 Sep 11.


Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.

Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J.

J Natl Compr Canc Netw. 2015 Sep;13(9):1102-10.


Lack of Support and Information Regarding Long-Term Negative Effects in Survivors of Rectal Cancer.

Sanoff HK, Morris W, Mitcheltree AL, Wilson S, Lund JL.

Clin J Oncol Nurs. 2015 Aug;19(4):444-8. doi: 10.1188/15.CJON.444-448.


Self-directed physical activity intervention in older adults undergoing adjuvant chemotherapy for colorectal cancer: Design of a randomized controlled trial.

Williams GR, Nyrop KA, Deal AM, Muss HB, Sanoff HK.

Contemp Clin Trials. 2015 May;42:90-7. doi: 10.1016/j.cct.2015.03.008. Epub 2015 Mar 28.


Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.

Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH.

Invest New Drugs. 2015 Apr;33(2):505-9. doi: 10.1007/s10637-015-0209-7. Epub 2015 Jan 23.


Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: a population-based, case-control study.

Quach C, Sanoff HK, Williams GR, Lyons JC, Reeve BB.

Cancer. 2015 Mar 15;121(6):943-50. doi: 10.1002/cncr.29125. Epub 2014 Nov 6.


Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.

Penn DC, Chang Y, Meyer AM, DeFilippo Mack C, Sanoff HK, Stitzenberg KB, Carpenter WR.

Cancer. 2015 Jan 1;121(1):93-101. doi: 10.1002/cncr.29028. Epub 2014 Sep 10.


Defining the toxicology of aging.

Sorrentino JA, Sanoff HK, Sharpless NE.

Trends Mol Med. 2014 Jul;20(7):375-84. doi: 10.1016/j.molmed.2014.04.004. Epub 2014 May 28. Review.


Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.

Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H.

PLoS One. 2014 Apr 11;9(4):e94727. doi: 10.1371/journal.pone.0094727. eCollection 2014.


Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, Ibrahim JG, Jolly TA, Williams G, Carey LA, Drobish A, Gordon BB, Alston S, Hurria A, Kleinhans K, Rudolph KL, Sharpless NE, Muss HB.

J Natl Cancer Inst. 2014 Apr;106(4):dju057. doi: 10.1093/jnci/dju057. Epub 2014 Mar 28.


Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.

Chakraborty S, Morris MM, Bauer TW, Adams RB, Stelow EB, Petroni G, Sanoff HK.

Gastrointest Cancer Res. 2014 Jan;7(1):15-22.


How we treat metastatic colon cancer in older adults.

Sanoff HK, Goldberg RM.

J Geriatr Oncol. 2013 Oct;4(4):295-301. doi: 10.1016/j.jgo.2013.07.007. Epub 2013 Aug 18.


Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation.

Cosgrove ND, Al-Osaimi AM, Sanoff HK, Morris MM, Read PW, Cox DG, Mann JA, Argo CK, Berg CL, Pelletier SJ, Maluf DG, Wang AY.

Am J Transplant. 2014 Feb;14(2):466-71. doi: 10.1111/ajt.12597. Epub 2013 Dec 26.


Practice patterns and long-term survival for early-stage rectal cancer.

Stitzenberg KB, Sanoff HK, Penn DC, Meyers MO, Tepper JE.

J Clin Oncol. 2013 Dec 1;31(34):4276-82. doi: 10.1200/JCO.2013.49.1860. Epub 2013 Oct 28.


Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.

Lund JL, Stürmer T, Sanoff HK, Brookhart A, Sandler RS, Warren JL.

Cancer. 2013 Jun 1;119(11):2038-47. doi: 10.1002/cncr.27991. Epub 2013 Mar 19.


Reply to H. Wong et al.

Sanoff HK, Carpenter WR, Stürmer T.

J Clin Oncol. 2013 Feb 1;31(4):512-3. No abstract available.


Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140. Epub 2012 Jun 4.


Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.

Carpenter WR, Meyer AM, Wu Y, Qaqish B, Sanoff HK, Goldberg RM, Weiner BJ.

Med Care. 2012 Aug;50(8):737-48. doi: 10.1097/MLR.0b013e31824ebe13.


Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422. Epub 2012 Jan 31.


Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.


Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.

Meyerhardt JA, Li L, Sanoff HK, Carpenter W 4th, Schrag D.

J Clin Oncol. 2012 Feb 20;30(6):608-15. doi: 10.1200/JCO.2011.38.9650. Epub 2012 Jan 17.


Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL.

Med Care. 2013 May;51(5):e27-34. doi: 10.1097/MLR.0b013e31823ab60f.


Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma.

Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH.

Gastrointest Cancer Res. 2011 May;4(3):78-83.


Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk.

Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE.

PLoS Genet. 2010 Dec 2;6(12):e1001233. doi: 10.1371/journal.pgen.1001233.


A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A, Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC.

Invest New Drugs. 2011 Oct;29(5):978-83. doi: 10.1007/s10637-010-9427-1. Epub 2010 Apr 13.


A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.

O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE.

Clin Colorectal Cancer. 2010 Apr;9(2):119-25. doi: 10.3816/CCC.2010.n.017.

Supplemental Content

Loading ...
Support Center